Valuation: Viatris Inc.

Market Cap 19.4B 17.02B 15.71B 14.52B 27.52B 1,858B 28.07B 189B 73.38B 909B 72.86B 71.26B 3,156B P/E 2026 *
61x
P/E 2027 * 26.4x
Enterprise Value 31.59B 27.71B 25.58B 23.64B 44.8B 3,025B 45.7B 308B 119B 1,480B 119B 116B 5,138B EV / Sales 2026 *
2.14x
EV / Sales 2027 * 2.02x
Free-Float
92.23%
Yield 2026 *
3.05%
Yield 2027 * 3.13%
1 day-0.84%
1 week+0.62%
Current month+2.92%
1 month+3.71%
3 months+23.96%
6 months+33.71%
Current year+36.90%
1 week 14.37
Extreme 14.374
14.89
1 month 13.21
Extreme 13.212
14.89
Current year 10.49
Extreme 10.49
14.95
1 year 7.51
Extreme 7.512
14.95
3 years 6.26
Extreme 6.262
14.95
5 years 6.26
Extreme 6.262
14.95
10 years 6.26
Extreme 6.262
15.5
Manager TitleAgeSince
Chief Executive Officer 63 01/04/2023
Director of Finance/CFO 59 08/05/2026
Chief Tech/Sci/R&D Officer - 15/12/2023
Director TitleAgeSince
Director/Board Member 78 16/11/2020
Director/Board Member 78 16/11/2020
Director/Board Member 62 16/11/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.84%+0.62% - - 19.75B
-1.60%+2.02%+56.34%+168.94% 1,102B
-1.44%+3.71%+69.07%+65.40% 643B
-0.75%+0.67%+33.18%+86.52% 450B
-1.35%+1.86%+29.96%+26.28% 336B
-0.86%+2.79%+37.72%+40.85% 298B
-0.71%+0.72%+28.85%+48.27% 288B
-1.31%-0.26%-28.18%-39.82% 222B
-0.03%+1.84%+23.90%+68.30% 199B
-0.40%+7.82%+22.29%+82.50% 169B
Average -0.93%+2.96%+30.35%+60.81% 411.78B
Weighted average by Cap. -1.16%+2.71%+41.37%+86.55%

Financials

2026 *2027 *
Net sales 14.77B 12.96B 11.96B 11.06B 20.95B 1,415B 21.37B 144B 55.88B 692B 55.48B 54.27B 2,403B 15.04B 13.19B 12.18B 11.25B 21.33B 1,440B 21.75B 146B 56.88B 705B 56.47B 55.23B 2,446B
Net income 13M 11.4M 10.52M 9.73M 18.43M 1.24B 18.8M 127M 49.16M 609M 48.81M 47.74M 2.11B 498M 436M 403M 372M 706M 47.64B 720M 4.84B 1.88B 23.31B 1.87B 1.83B 80.93B
Net Debt 12.19B 10.69B 9.87B 9.12B 17.28B 1,167B 17.63B 119B 46.1B 571B 45.76B 44.76B 1,982B 11.03B 9.67B 8.93B 8.25B 15.64B 1,056B 15.96B 107B 41.72B 517B 41.42B 40.52B 1,794B
Logo Viatris Inc.
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
30,000
Date Price Change
08/07/26 €14.48 -2.77%
07/07/26 €14.89 +1.50%
06/07/26 €14.67 +2.06%
03/07/26 €14.37 -0.84%
02/07/26 €14.50 +1.47%
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
16.66USD
Average target price
17.81USD
Spread / Average Target
+6.92%

Quarterly revenue - Rate of surprise